Integration of diagnostic and therapeutic
functions in a single
platform namely theranostics has become a cornerstone for personalized
medicine. Theranostics platform facilitates noninvasive detection
and treatment while allowing the monitoring of disease progression
and therapeutic efficacy in case of chronic conditions of cancer and
Alzheimer’s disease (AD). Theranostic tools function by themselves
or with the aid of carrier, viz. liposomes, micelles,
polymers, or dendrimers. The dendrimer architectures (DA) are well-characterized
molecular nanoobjects with a large number of terminal functional groups
to enhance solubility and offer multivalency and multifunctional properties.
Various noninvasive diagnostic tools like magnetic resonance imaging
(MRI), computed tomography (CT), gamma scintigraphy, and optical techniques
have been accomplished utilizing DAs for simultaneous imaging and
drug delivery. Obstacles in the formulation design, drug loading,
payload delivery, biocompatibility, overcoming cellular membrane and
blood–brain barrier (BBB), and systemic circulation remain
a bottleneck in translational efforts. This review focuses on the
diagnostic, therapeutic and theranostic potential of DA-based nanocarriers
in treating cancer and neurodegenerative disorders like AD and Parkinson’s
disease (PD), among others. In view of the inverse relationship between
cancer and AD, designing suitable DA-based theranostic nanodrug with
high selectivity has tremendous implications in personalized medicine
to treat cancer and neurodegenerative disorders.